Investors and Collaborators

The i-Slide and the i-Assay product lines are leading pre-clinical protein research tools, used by researchers to further enhance their experimental methods and results. These product lines are currently supplied by Inanovate direct to end users, however Inanovate is in discussions with a variety of biochip/device, assay, and diagnostic companies, regarding collaborative / partnership arrangements to leverage established distribution networks, marketing and sales presence, and financial resources.

The i-Screen is scheduled for entry into a Device Master Filing in the first half of 2009, with the first integrated diagnostic test (for prostate cancer), planned for entry into PMA procedures later that year. To support this entry application, Inanovate has in-licensed proprietary auto-antibody biomarkers.

The i-Screen 'product' sold to diagnostic channel partners will include the physical disposable substrate alongside a one time license to the screening procedure required to process the test, and where applicable a license to biomarker content. This disposable chip will be supported by low cost, desk top hardware to process the tests.

There are five strategic areas of focus supporting Inanovate’s business model: (i) Operational excellence on substrate production; (ii) Market leadership position in substrate performance; (iii) Extensive IP protection on the substrates and the manufacturing systems used to make them; (iv) Control of key value added IP for diagnostic applications; (v) Generation of supporting revenue through use of expertise and facilities.